ReviewCancer immunology, immunotherapy : CII2019
Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT.
Review in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06388252 (Electrochemotherapy Induces Changes in the Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Patients With Cutaneous Melanoma), which is not on this map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Electrochemotherapy Induces Changes in the Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Patients With Cutaneous Melanoma
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- The value ofEuropean journal of nuclear medicine and molecular imaging · 2021Pooled it
- Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process-A systematic review.Cancer medicine · 2020Pooled it
- Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial.Journal for immunotherapy of cancer · 2025Trial
- Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR.Molecular diagnosis & therapy · 2026Article
- Article
- This union must happen: Radiomics and LAFOV PET/CT as the power couple of nuclear medicine.European journal of nuclear medicine and molecular imaging · 2025Article
- Endoscopic and imaging evaluations of the primary tumor response in patients with proficient mismatch repair colorectal cancer treated with neoadjuvant combination immunotherapy.Techniques in coloproctology · 2025Observational
- It Looks Like a Zebra but Is Not: [Diagnostics (Basel, Switzerland) · 2024Article
- Non-[Pharmaceuticals (Basel, Switzerland) · 2024Review
- Review on radiomic analysis inCancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Can physiologic colonic [European journal of nuclear medicine and molecular imaging · 2023Article
- Long axial field of view (LAFOV) PET-CT: implementation in static and dynamic oncological studies.European journal of nuclear medicine and molecular imaging · 2023Review
- Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach?International journal of molecular sciences · 2023Review
- Immuno-Imaging (PET/SPECT)-Quo Vadis?Molecules (Basel, Switzerland) · 2022Review
- Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.European journal of nuclear medicine and molecular imaging · 2022Article
- The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Review
- Pitfalls on PET/CT Due to Artifacts and Instrumentation.Seminars in nuclear medicine · 2021Review
- Article
- [European journal of nuclear medicine and molecular imaging · 2021Article
- Imaging in Tumor Immunology.Nuclear medicine and molecular imaging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Immune checkpoint inhibitors (ICI) have revolutionized therapy of metastatic melanoma. The first ICI was ipilimumab, a cytotoxic T lymphocyte-associated Ag 4 (CLTA-4) inhibitor with response rates of approximately 11% and disease control of 22%. The programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab and nivolumab, led to longer progression-free survival and overall survival rates with fewer side effects. Molecular imaging techniques, such as positron emission tomography-computed tomography (PET-CT) with 2-deoxy-2-(
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.